Master Your GLP-1 Clinical Trials with Certainty
Navigate your GLP-1 clinical trials with confidence. YPrime’s GLP-1 Playbook equips you with essential strategies to implement eCOA effectively, while highlighting key pitfalls to avoid to improve your clinical research.
Why You Need This Playbook
The GLP-1 market is projected to reach $157.5 billion by 2035.1 With over 300 drugs in development2 and leading medications achieving 15-22% mean weight loss,3 the pressure to optimize trial operations has never been greater.
As GLP-1 research advances, these promising areas highlight the expanding potential of this important drug class beyond weight management and diabetes treatment, including:

YPrime has supported numerous GLP-1 clinical trials for both top global pharma leaders and emerging biotechs, delivering both eCOA and IRT. In one study, YPrime supported 10,000+ patients globally with our industry-leading eCOA platform.
Access Our New GLP-1 Playbook and Discover
If you are a clinical trial sponsor or CRO working in clinical operations, study management, therapeutic excellence, or eClinical technology, download this important playbook and equip yourself to drive greater efficiency in GLP-1 clinical trials.
- Roots Analysis Business Research & Consulting, GLP-1 Market: Industry Trends and Global Forecasts. https://www.rootsanalysis.com/reports/glp-1-market.html. Accessed January 27, 2025.
- Clinical Trials Arena, 2024 was a record year for obesity trials and 2025 is already poised to take over. https://www.clinicaltrialsarena.com/analyst-comment/2024-record-year-obesity-trials-2025-poised-take-over/. Accessed January 27, 2025.
- CBS News Healthwatch, As many as 1 in 5 people won’t lose weight with GLP-1 drugs, experts say. https://www.cbsnews.com/news/1-in-5-people-wont-lose-weight-glp-1-drugs-experts/. Accessed January 27, 2025.